-
1
-
-
2442626359
-
Use of diagnostic testing for managing hepatitis C virus infection
-
Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004;24 Suppl 2:9-18
-
(2004)
Semin Liver Dis
, vol.24
, Issue.SUPPL. 2
, pp. 9-18
-
-
Ferreira-Gonzalez, A.1
Shiffman, M.L.2
-
2
-
-
30144435324
-
HCV virological assessment
-
Forns X, Costa J. HCV virological assessment. J Hepatol 2006;44:S35-S39
-
(2006)
J Hepatol
, vol.44
-
-
Forns, X.1
Costa, J.2
-
3
-
-
22044444011
-
Use of virologic assays in the diagnosis and management of hepatitis C virus infection
-
v
-
Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005; 9:371-382, v
-
(2005)
Clin Liver Dis
, vol.9
, pp. 371-382
-
-
Chevaliez, S.1
Pawlotsky, J.M.2
-
4
-
-
0037423405
-
Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus
-
Centers for Disease Control and Prevention, (quiz CE1-4)
-
Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1-1315. (quiz CE1-4)
-
(2003)
MMWR Recomm Rep
, vol.52
, pp. 1-1315
-
-
Alter, M.J.1
Kuhnert, W.L.2
Finelli, L.3
-
5
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
6
-
-
0032954992
-
Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
-
WHO Collaborative Study Group
-
Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999;76:149-158
-
(1999)
Vox Sang
, vol.76
, pp. 149-158
-
-
Saldanha, J.1
Lelie, N.2
Heath, A.3
-
7
-
-
34247216563
-
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
-
McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-633
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 615-633
-
-
McCaughan, G.W.1
Omata, M.2
Amarapurkar, D.3
Bowden, S.4
Chow, W.C.5
Chutaputti, A.6
-
8
-
-
0033854022
-
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA
-
Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000;32:388-393
-
(2000)
Hepatology
, vol.32
, pp. 388-393
-
-
Tanaka, E.1
Ohue, C.2
Aoyagi, K.3
Yamaguchi, K.4
Yagi, S.5
Kiyosawa, K.6
-
9
-
-
33644795532
-
Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?
-
Laperche S, Elghouzzi MH, Morel P, Asso-Bonnet M, Le Marrec N, Girault A, et al. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005;45:1965-1972
-
(2005)
Transfusion
, vol.45
, pp. 1965-1972
-
-
Laperche, S.1
Elghouzzi, M.H.2
Morel, P.3
Asso-Bonnet, M.4
Le Marrec, N.5
Girault, A.6
-
10
-
-
79960344983
-
Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting
-
Ergunay K, Sener B, Alp A, Karakaya J, Hascelik G. Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 2011;70:486-491
-
(2011)
Diagn Microbiol Infect Dis
, vol.70
, pp. 486-491
-
-
Ergunay, K.1
Sener, B.2
Alp, A.3
Karakaya, J.4
Hascelik, G.5
-
11
-
-
79960341459
-
Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups
-
Yang JF, Lin YY, Hsieh MH, Tsai CH, Liu SF, Yu ML, et al. Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. Kaohsiung J Med Sci 2011;27:258-263
-
(2011)
Kaohsiung J Med Sci
, vol.27
, pp. 258-263
-
-
Yang, J.F.1
Lin, Y.Y.2
Hsieh, M.H.3
Tsai, C.H.4
Liu, S.F.5
Yu, M.L.6
-
12
-
-
25844523297
-
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
-
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-973
-
(2005)
Hepatology
, vol.42
, pp. 962-973
-
-
Simmonds, P.1
Bukh, J.2
Combet, C.3
Deleage, G.4
Enomoto, N.5
Feinstone, S.6
-
13
-
-
33748694270
-
Chronic hepatitis C virus infection: Genotyping and its clinical role
-
Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol 2006;1:103-112
-
(2006)
Future Microbiol
, vol.1
, pp. 103-112
-
-
Bowden, D.S.1
Berzsenyi, M.D.2
-
14
-
-
77955509605
-
Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans
-
Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, et al. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int 2010;4:523-529
-
(2010)
Hepatol Int
, vol.4
, pp. 523-529
-
-
Nguyen, N.H.1
Vutien, P.2
Trinh, H.N.3
Garcia, R.T.4
Nguyen, L.H.5
Nguyen, H.A.6
-
15
-
-
45149105859
-
Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0
-
Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008;46:1901-1906
-
(2008)
J Clin Microbiol
, vol.46
, pp. 1901-1906
-
-
Verbeeck, J.1
Stanley, M.J.2
Shieh, J.3
Celis, L.4
Huyck, E.5
Wollants, E.6
-
16
-
-
56149095245
-
Interpretation of positive transcriptionmediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
-
Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, et al. Interpretation of positive transcriptionmediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008;48:1412-1419
-
(2008)
Hepatology
, vol.48
, pp. 1412-1419
-
-
Morishima, C.1
Morgan, T.R.2
Everhart, J.E.3
Wright, E.C.4
Apodaca, M.C.5
Gretch, D.R.6
-
17
-
-
78049499788
-
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a communitybased cohort study
-
Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a communitybased cohort study. J Clin Oncol 2010;28:4587-4593
-
(2010)
J Clin Oncol
, vol.28
, pp. 4587-4593
-
-
Lee, M.H.1
Yang, H.I.2
Lu, S.N.3
Jen, C.L.4
Yeh, S.H.5
Liu, C.J.6
-
18
-
-
34147207791
-
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
-
Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559
-
(2007)
Gut
, vol.56
, pp. 553-559
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
Hou, N.J.4
Lee, L.P.5
Hsieh, M.Y.6
-
19
-
-
46249114151
-
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
-
Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-1893
-
(2008)
Hepatology
, vol.47
, pp. 1884-1893
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
Chiu, C.F.4
Yang, Y.H.5
Hou, N.J.6
-
20
-
-
73449094187
-
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: A meta-analysis
-
Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther 2009;14:1139-1148
-
(2009)
Antivir Ther
, vol.14
, pp. 1139-1148
-
-
Slavenburg, S.1
Weggelaar, I.2
Van Oijen, M.G.3
Drenth, J.P.4
-
21
-
-
71349085573
-
Shortened treatment duration in treatment-nai7die;ve genotype 1 HCV patients with rapid virological response: A meta-analysis
-
Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-nai7die;ve genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010;52:25-31
-
(2010)
J Hepatol
, vol.52
, pp. 25-31
-
-
Moreno, C.1
Deltenre, P.2
Pawlotsky, J.M.3
Henrion, J.4
Adler, M.5
Mathurin, P.6
-
22
-
-
84984562129
-
Pegylated interferon-alpha-2a plus ribavirin for treatment-nai7die;ve Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
-
Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-nai7die;ve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269
-
(2008)
Clin Infect Dis
, vol.47
, pp. 1260-1269
-
-
Liu, C.H.1
Liu, C.J.2
Lin, C.L.3
Liang, C.C.4
Hsu, S.J.5
Yang, S.S.6
-
23
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
-
24
-
-
34547395999
-
Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method
-
Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007;46:22-31
-
(2007)
Hepatology
, vol.46
, pp. 22-31
-
-
Chevaliez, S.1
Bouvier-Alias, M.2
Brillet, R.3
Pawlotsky, J.M.4
-
25
-
-
65449189713
-
The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples
-
Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 2009;49:1397-1398
-
(2009)
Hepatology
, vol.49
, pp. 1397-1398
-
-
Chevaliez, S.1
Bouvier-Alias, M.2
Castera, L.3
Pawlotsky, J.M.4
-
26
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
-
27
-
-
77950597305
-
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
-
Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122-1126
-
(2010)
Hepatology
, vol.51
, pp. 1122-1126
-
-
Martinot-Peignoux, M.1
Stern, C.2
Maylin, S.3
Ripault, M.P.4
Boyer, N.5
Leclere, L.6
-
28
-
-
80052714532
-
Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C
-
Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, et al. Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011;52:133-137
-
(2011)
J Clin Virol
, vol.52
, pp. 133-137
-
-
Vermehren, J.1
Yu, M.L.2
Monto, A.3
Yao, J.D.4
Anderson, C.5
Bertuzis, R.6
-
29
-
-
40149083761
-
Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial
-
Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat 2008;15:250-254
-
(2008)
J Viral Hepat
, vol.15
, pp. 250-254
-
-
Hickman, M.1
McDonald, T.2
Judd, A.3
Nichols, T.4
Hope, V.5
Skidmore, S.6
-
30
-
-
77955051727
-
Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots
-
Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat 2011;18:262-270
-
(2011)
J Viral Hepat
, vol.18
, pp. 262-270
-
-
Hope, V.D.1
Hickman, M.2
Ngui, S.L.3
Jones, S.4
Telfer, M.5
Bizzarri, M.6
-
31
-
-
65049086383
-
Liver fibrosis: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)
-
Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3:323-333
-
(2009)
Hepatol Int
, vol.3
, pp. 323-333
-
-
Shiha, G.1
Sarin, S.K.2
Ibrahim, A.E.3
Omata, M.4
Kumar, A.5
Lesmana, L.A.6
-
32
-
-
79952223130
-
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis
-
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736
-
(2011)
Hepatology
, vol.53
, pp. 726-736
-
-
Zh, L.1
Xin, Y.N.2
Dong, Q.J.3
Wang, Q.4
Jiang, X.J.5
Zhan, S.H.6
-
33
-
-
50849094538
-
A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: A comparison using histology with internal-external validation
-
Paggi S, Colli A, Fraquelli M, Vigano M, Del Poggio P, Facciotto C, et al. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol 2008;49:564-571
-
(2008)
J Hepatol
, vol.49
, pp. 564-571
-
-
Paggi, S.1
Colli, A.2
Fraquelli, M.3
Vigano, M.4
Del Poggio, P.5
Facciotto, C.6
-
34
-
-
63549120137
-
SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C
-
Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1821-1827
-
(2009)
Hepatology
, vol.49
, pp. 1821-1827
-
-
Sebastiani, G.1
Halfon, P.2
Castera, L.3
Pol, S.4
Thomas, D.L.5
Mangia, A.6
-
35
-
-
75349088230
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C
-
Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198
-
(2010)
J Hepatol
, vol.52
, pp. 191-198
-
-
Castera, L.1
Sebastiani, G.2
Le Bail, B.3
De Ledinghen, V.4
Couzigou, P.5
Alberti, A.6
-
36
-
-
33751018880
-
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy
-
Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006;44:1086-1097
-
(2006)
Hepatology
, vol.44
, pp. 1086-1097
-
-
Yu, M.L.1
Lin, S.M.2
Lee, C.M.3
Dai, C.Y.4
Chang, W.Y.5
Chen, S.C.6
-
37
-
-
77957197697
-
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
-
Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-1409
-
(2010)
Gut
, vol.59
, pp. 1401-1409
-
-
Fontana, R.J.1
Dienstag, J.L.2
Bonkovsky, H.L.3
Sterling, R.K.4
Naishadham, D.5
Goodman, Z.D.6
-
38
-
-
68949107512
-
Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography
-
Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49:1954-1961
-
(2009)
Hepatology
, vol.49
, pp. 1954-1961
-
-
Masuzaki, R.1
Tateishi, R.2
Yoshida, H.3
Goto, E.4
Sato, T.5
Ohki, T.6
-
39
-
-
73449143487
-
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation
-
Carrion JA, Torres F, Crespo G, Miquel R, Garcia-Valdecasas JC, Navasa M, et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010;51:23-34
-
(2010)
Hepatology
, vol.51
, pp. 23-34
-
-
Carrion, J.A.1
Torres, F.2
Crespo, G.3
Miquel, R.4
Garcia-Valdecasas, J.C.5
Navasa, M.6
-
40
-
-
72549096288
-
Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation
-
Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138:147-158 e1
-
(2010)
Gastroenterology
, vol.138
-
-
Carrion, J.A.1
Fernandez-Varo, G.2
Bruguera, M.3
Garcia-Pagan, J.C.4
Garcia-Valdecasas, J.C.5
Perez-Del-Pulgar, S.6
-
41
-
-
79958103937
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C
-
1979 e1-3
-
Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140:1970-1979, 1979 e1-3
-
(2011)
Gastroenterology
, vol.140
, pp. 1970-1979
-
-
Vergniol, J.1
Foucher, J.2
Terrebonne, E.3
Bernard, P.H.4
Le Bail, B.5
Merrouche, W.6
-
42
-
-
74549128529
-
Epidemiology of hepatitis B and C viruses: A global overview
-
vii
-
Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21, vii
-
(2010)
Clin Liver Dis
, vol.14
, pp. 1-21
-
-
Te, H.S.1
Jensen, D.M.2
-
43
-
-
79956138217
-
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus
-
Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011;54:1273-1285
-
(2011)
J Hepatol
, vol.54
, pp. 1273-1285
-
-
Torresi, J.1
Johnson, D.2
Wedemeyer, H.3
-
44
-
-
4944229012
-
Hepatitis C: Who is at risk and how do we identify them?
-
Goldberg D, Anderson E. Hepatitis C: who is at risk and how do we identify them? J Viral Hepat 2004;11 Suppl 1:12-18
-
(2004)
J Viral Hepat
, vol.11
, Issue.SUPPL. 1
, pp. 12-18
-
-
Goldberg, D.1
Anderson, E.2
-
45
-
-
0033931381
-
Transmission of hepatitis C virus in Asia: Past and present perspectives
-
Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000;15 Suppl:E91-E96
-
(2000)
J Gastroenterol Hepatol
, vol.15 SUPPL.
-
-
Kao, J.H.1
Chen, D.S.2
-
47
-
-
66549114612
-
Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa
-
Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-1125
-
(2009)
Transfusion
, vol.49
, pp. 1115-1125
-
-
Vermeulen, M.1
Lelie, N.2
Sykes, W.3
Crookes, R.4
Swanevelder, J.5
Gaggia, L.6
-
48
-
-
35448938475
-
A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing
-
Shan H, Ren FR, Zhao HY, Zhang YZ, Wen GX, Yao FZ, et al. A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing. Transfusion 2007;47:2011-2016
-
(2007)
Transfusion
, vol.47
, pp. 2011-2016
-
-
Shan, H.1
Ren, F.R.2
Zhao, H.Y.3
Zhang, Y.Z.4
Wen, G.X.5
Yao, F.Z.6
-
49
-
-
33748253275
-
Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review
-
Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006;45:607-616
-
(2006)
J Hepatol
, vol.45
, pp. 607-616
-
-
Prati, D.1
-
50
-
-
34548489173
-
Global estimates of prevalence of HCV infection among injecting drug users
-
Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18:352-358
-
(2007)
Int J Drug Policy
, vol.18
, pp. 352-358
-
-
Aceijas, C.1
Rhodes, T.2
-
51
-
-
34648835639
-
Injecting alone among young adult IDUs in five US cities: Evidence of low rates of injection risk behavior
-
Hagan H, Campbell JV, Thiede H, Strathdee SA, Ouellet L, Latka M, et al. Injecting alone among young adult IDUs in five US cities: evidence of low rates of injection risk behavior. Drug Alcohol Depend 2007;91 Suppl 1:S48-S55
-
(2007)
Drug Alcohol Depend
, vol.91
, Issue.SUPPL. 1
-
-
Hagan, H.1
Campbell, J.V.2
Thiede, H.3
Strathdee, S.A.4
Ouellet, L.5
Latka, M.6
-
52
-
-
44949210418
-
High prevalence of hepatitis C virus infection among noninjecting drug users: Association with sharing the inhalation implements of crack
-
Macias J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int 2008;28:781-786
-
(2008)
Liver Int
, vol.28
, pp. 781-786
-
-
MacIas, J.1
Palacios, R.B.2
Claro, E.3
Vargas, J.4
Vergara, S.5
Mira, J.A.6
-
53
-
-
77950661287
-
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews
-
Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010;105:844-859
-
(2010)
Addiction
, vol.105
, pp. 844-859
-
-
Palmateer, N.1
Kimber, J.2
Hickman, M.3
Hutchinson, S.4
Rhodes, T.5
Goldberg, D.6
-
54
-
-
40149083125
-
Risk of hepatitis C virus transmission through drug preparation equipment: A systematic and methodological review
-
De P, Roy E, Boivin JF, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat 2008;15:279-292
-
(2008)
J Viral Hepat
, vol.15
, pp. 279-292
-
-
De P Roy, E.1
Boivin, J.F.2
Cox, J.3
Morissette, C.4
-
55
-
-
77955878462
-
Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients
-
Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010;56:371-378
-
(2010)
Am J Kidney Dis
, vol.56
, pp. 371-378
-
-
Patel, P.R.1
Thompson, N.D.2
Kallen, A.J.3
Arduino, M.J.4
-
56
-
-
0035957964
-
Recommendations for preventing transmission of infections among chronic hemodialysis patients
-
Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1-43
-
(2001)
MMWR Recomm Rep
, vol.50
, pp. 1-43
-
-
-
57
-
-
61449184675
-
Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients
-
Ross RS, Viazov S, Clauberg R, Wolters B, Fengler I, Eveld K, et al. Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. J Viral Hepat 2009;16:230-238
-
(2009)
J Viral Hepat
, vol.16
, pp. 230-238
-
-
Ross, R.S.1
Viazov, S.2
Clauberg, R.3
Wolters, B.4
Fengler, I.5
Eveld, K.6
-
58
-
-
67650803421
-
The German Hep-Net acute hepatitis C cohort: Impact of viral and host factors on the initial presentation of acute hepatitis C virus infection
-
Deterding K, Wiegand J, Gruner N, Hahn A, Jackel E, Jung MC, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009;47:531-540
-
(2009)
Z Gastroenterol
, vol.47
, pp. 531-540
-
-
Deterding, K.1
Wiegand, J.2
Gruner, N.3
Hahn, A.4
Jackel, E.5
Jung, M.C.6
-
59
-
-
34447317106
-
Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years)
-
de Ledinghen V, Trimoulet P, Mannant PR, Dumas F, Champbenoit P, Baldit C, et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 2007;46:19-25
-
(2007)
J Hepatol
, vol.46
, pp. 19-25
-
-
De Ledinghen, V.1
Trimoulet, P.2
Mannant, P.R.3
Dumas, F.4
Champbenoit, P.5
Baldit, C.6
-
60
-
-
77953904186
-
Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures
-
Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology 2010;139:163-170
-
(2010)
Gastroenterology
, vol.139
, pp. 163-170
-
-
Gutelius, B.1
Perz, J.F.2
Parker, M.M.3
Hallack, R.4
Stricof, R.5
Clement, E.J.6
-
61
-
-
33750347505
-
Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies
-
Patel PR, Larson AK, Castel AD, Ganova-Raeva LM, Myers RA, Roup BJ, et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA 2006;296:2005-2011
-
(2006)
JAMA
, vol.296
, pp. 2005-2011
-
-
Patel, P.R.1
Larson, A.K.2
Castel, A.D.3
Ganova-Raeva, L.M.4
Myers, R.A.5
Roup, B.J.6
-
62
-
-
1642329320
-
Unsafe injections in low-income country health settings: Need for injection safety promotion to prevent the spread of blood-borne viruses
-
Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 2004;19:95-103
-
(2004)
Health Promot Int
, vol.19
, pp. 95-103
-
-
Kermode, M.1
-
63
-
-
0032726232
-
Unsafe injections in the developing world and transmission of bloodborne pathogens: A review
-
Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999;77:789-800
-
(1999)
Bull World Health Organ
, vol.77
, pp. 789-800
-
-
Simonsen, L.1
Kane, A.2
Lloyd, J.3
Zaffran, M.4
Kane, M.5
-
64
-
-
0029062792
-
Transmission of hepatitis C virus by health care workers in a rural area of Japan
-
Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 1995;90:794-799
-
(1995)
Am J Gastroenterol
, vol.90
, pp. 794-799
-
-
Hayashi, J.1
Kishihara, Y.2
Yamaji, K.3
Yoshimura, E.4
Kawakami, Y.5
Akazawa, K.6
-
65
-
-
0034879029
-
Body piercing as a risk factor for viral hepatitis: An integrative research review
-
Hayes MO, Harkness GA. Body piercing as a risk factor for viral hepatitis: an integrative research review. Am J Infect Control 2001;29:271-274
-
(2001)
Am J Infect Control
, vol.29
, pp. 271-274
-
-
Hayes, M.O.1
Harkness, G.A.2
-
66
-
-
78149464412
-
Tattooing and the risk of transmission of hepatitis C: A systematic review and meta-analysis
-
Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010;14:e928-e940
-
(2010)
Int J Infect Dis
, vol.14
-
-
Jafari, S.1
Copes, R.2
Baharlou, S.3
Etminan, M.4
Buxton, J.5
-
67
-
-
0344873287
-
Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies
-
Ernst E, Sherman KJ. Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies. J Gastroenterol Hepatol 2003;18:1231-1236
-
(2003)
J Gastroenterol Hepatol
, vol.18
, pp. 1231-1236
-
-
Ernst, E.1
Sherman, K.J.2
-
68
-
-
0034025691
-
Intrafamilial transmission of hepatitis C virus: A systematic review
-
Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat 2000;7:93-103
-
(2000)
J Viral Hepat
, vol.7
, pp. 93-103
-
-
Ackerman, Z.1
Ackerman, E.2
Paltiel, O.3
-
69
-
-
27944447629
-
A significant sex-but not elective cesarean section-effect on mother-tochild transmission of hepatitis C virus infection
-
European Paediatric Hepatitis C Virus Network
-
European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-tochild transmission of hepatitis C virus infection. J Infect Dis 2005;192:1872-1879
-
(2005)
J Infect Dis
, vol.192
, pp. 1872-1879
-
-
-
70
-
-
78751706564
-
Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA?/HIV-mothers: A meta-analysis
-
Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA?/HIV-mothers: a meta-analysis. Arch Gynecol Obstet 2011;283:255-260
-
(2011)
Arch Gynecol Obstet
, vol.283
, pp. 255-260
-
-
Ghamar Chehreh, M.E.1
Tabatabaei, S.V.2
Khazanehdari, S.3
Alavian, S.M.4
-
71
-
-
77957955905
-
Is sexual contact a major mode of hepatitis C virus transmission?
-
Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52:1497-1505
-
(2010)
Hepatology
, vol.52
, pp. 1497-1505
-
-
Tohme, R.A.1
Holmberg, S.D.2
-
72
-
-
33746078148
-
Seroprevalence and risk factors for hepatitis C virus infection among female commercial sex workers in South Korea who are not intravenous drug users
-
Kweon SS, Shin MH, Song HJ, Jeon DY, Choi JS. Seroprevalence and risk factors for hepatitis C virus infection among female commercial sex workers in South Korea who are not intravenous drug users. Am J Trop Med Hyg 2006;74:1117-1121
-
(2006)
Am J Trop Med Hyg
, vol.74
, pp. 1117-1121
-
-
Kweon, S.S.1
Shin, M.H.2
Song, H.J.3
Jeon, D.Y.4
Choi, J.S.5
-
73
-
-
34250304649
-
Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs
-
Buffington J, Murray PJ, Schlanger K, Shih L, Badsgard T, Hennessy RR, et al. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs. Public Health Rep 2007;122 Suppl 2:63-67
-
(2007)
Public Health Rep
, vol.122
, Issue.SUPPL. 2
, pp. 63-67
-
-
Buffington, J.1
Murray, P.J.2
Schlanger, K.3
Shih, L.4
Badsgard, T.5
Hennessy, R.R.6
-
74
-
-
0033382086
-
Epidemiology of hepatitis C in the United States
-
Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S
-
(1999)
Am J Med
, vol.107
-
-
Williams, I.1
-
75
-
-
67649939233
-
Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan
-
Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 2009;81:1189-1197
-
(2009)
J Med Virol
, vol.81
, pp. 1189-1197
-
-
Khan, A.1
Tanaka, Y.2
Azam, Z.3
Abbas, Z.4
Kurbanov, F.5
Saleem, U.6
-
76
-
-
0033406372
-
Hepatitis C: The clinical spectrum of the disease
-
Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31 Suppl 1:9-16
-
(1999)
J Hepatol
, vol.31
, Issue.SUPPL. 1
, pp. 9-16
-
-
Marcellin, P.1
-
77
-
-
33644875265
-
Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies
-
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41
-
(2006)
J Viral Hepat
, vol.13
, pp. 34-41
-
-
Micallef, J.M.1
Kaldor, J.M.2
Dore, G.J.3
-
78
-
-
0026786275
-
Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors
-
McCaughan GW, McGuinness PH, Bishop GA, Painter DM, Lien AS, Tulloch R, et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med J Aust 1992;157:231-233
-
(1992)
Med J Aust
, vol.157
, pp. 231-233
-
-
McCaughan, G.W.1
McGuinness, P.H.2
Bishop, G.A.3
Painter, D.M.4
Lien, A.S.5
Tulloch, R.6
-
79
-
-
0033932001
-
Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
-
Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35
-
(2000)
Semin Liver Dis
, vol.20
, pp. 17-35
-
-
Alter, H.J.1
Seeff, L.B.2
-
80
-
-
0035914925
-
Determinants of viral clearance and persistence during acute hepatitis C virus infection
-
Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406
-
(2001)
J Exp Med
, vol.194
, pp. 1395-1406
-
-
Thimme, R.1
Oldach, D.2
Chang, K.M.3
Steiger, C.4
Ray, S.C.5
Chisari, F.V.6
-
81
-
-
0025882948
-
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
-
Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104
-
(1991)
N Engl J Med
, vol.325
, pp. 98-104
-
-
Farci, P.1
Alter, H.J.2
Wong, D.3
Miller, R.H.4
Shih, J.W.5
Jett, B.6
-
82
-
-
0029799762
-
Hepatitis C virus-associated fulminant hepatic failure
-
Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-634
-
(1996)
N Engl J Med
, vol.335
, pp. 631-634
-
-
Farci, P.1
Alter, H.J.2
Shimoda, A.3
Govindarajan, S.4
Cheung, L.C.5
Melpolder, J.C.6
-
83
-
-
14644386813
-
Acute hepatitis C: A multifaceted disease
-
Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005;25:7-17
-
(2005)
Semin Liver Dis
, vol.25
, pp. 7-17
-
-
Heller, T.1
Rehermann, B.2
-
85
-
-
2342533783
-
Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial
-
Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004;39:1213-1219
-
(2004)
Hepatology
, vol.39
, pp. 1213-1219
-
-
Nomura, H.1
Sou, S.2
Tanimoto, H.3
Nagahama, T.4
Kimura, Y.5
Hayashi, J.6
-
86
-
-
20144389199
-
Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres
-
Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005;42:646-651
-
(2005)
J Hepatol
, vol.42
, pp. 646-651
-
-
Sagnelli, E.1
Coppola, N.2
Marrocco, C.3
Coviello, G.4
Battaglia, M.5
Messina, V.6
-
87
-
-
70349415455
-
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria
-
McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009;49:1051-1060
-
(2009)
Clin Infect Dis
, vol.49
, pp. 1051-1060
-
-
McGovern, B.H.1
Birch, C.E.2
Bowen, M.J.3
Reyor, L.L.4
Nagami, E.H.5
Chung, R.T.6
-
88
-
-
75149193915
-
Early treatment improves outcomes in acute hepatitis C virus infection: A meta-analysis
-
Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010;17:201-207
-
(2010)
J Viral Hepat
, vol.17
, pp. 201-207
-
-
Corey, K.E.1
Mendez-Navarro, J.2
Gorospe, E.C.3
Zheng, H.4
Chung, R.T.5
-
89
-
-
0033023854
-
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
-
Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914
-
(1999)
Hepatology
, vol.29
, pp. 908-914
-
-
Villano, S.A.1
Vlahov, D.2
Nelson, K.E.3
Cohn, S.4
Thomas, D.L.5
-
90
-
-
0038575483
-
Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
-
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88
-
(2003)
Gastroenterology
, vol.125
, pp. 80-88
-
-
Gerlach, J.T.1
Diepolder, H.M.2
Zachoval, R.3
Gruener, N.H.4
Jung, M.C.5
Ulsenheimer, A.6
-
91
-
-
2342588971
-
High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection
-
Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004;73:387-391
-
(2004)
J Med Virol
, vol.73
, pp. 387-391
-
-
Lehmann, M.1
Meyer, M.F.2
Monazahian, M.3
Tillmann, H.L.4
Manns, M.P.5
Wedemeyer, H.6
-
92
-
-
0037222767
-
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
-
Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003;37:60-64
-
(2003)
Hepatology
, vol.37
, pp. 60-64
-
-
Hofer, H.1
Watkins-Riedel, T.2
Janata, O.3
Penner, E.4
Holzmann, H.5
Steindl-Munda, P.6
-
93
-
-
70349966196
-
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
-
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
-
(2009)
Nature
, vol.461
, pp. 798-801
-
-
Thomas, D.L.1
Thio, C.L.2
Martin, M.P.3
Qi, Y.4
Ge, D.5
O'huigin, C.6
-
94
-
-
77954225315
-
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes
-
Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33-37
-
(2010)
Hepatology
, vol.52
, pp. 33-37
-
-
Montes-Cano, M.A.1
Garcia-Lozano, J.R.2
Abad-Molina, C.3
Romero-Gomez, M.4
Barroso, N.5
Aguilar-Reina, J.6
-
95
-
-
78049469161
-
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
-
1592 e1
-
Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586-1592, 1592 e1
-
(2010)
Gastroenterology
, vol.139
, pp. 1586-1592
-
-
Tillmann, H.L.1
Thompson, A.J.2
Patel, K.3
Wiese, M.4
Tenckhoff, H.5
Nischalke, H.D.6
-
96
-
-
0036829816
-
Natural history of chronic hepatitis C
-
Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46
-
(2002)
Hepatology
, vol.36
-
-
Seeff, L.B.1
-
97
-
-
78751476825
-
Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients
-
Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011;53:367-368
-
(2011)
Hepatology
, vol.53
, pp. 367-368
-
-
Huang, C.F.1
Dai, C.Y.2
Huang, J.F.3
Chuang, W.L.4
Yu, M.L.5
-
98
-
-
63049089916
-
Treatment of chronic hepatitis C in Asia: When East meets West
-
Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345
-
(2009)
J Gastroenterol Hepatol
, vol.24
, pp. 336-345
-
-
Yu, M.L.1
Chuang, W.L.2
-
99
-
-
33646250428
-
The natural history of hepatitis C virus (HCV) infection
-
Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
-
(2006)
Int J Med Sci
, vol.3
, pp. 47-52
-
-
Chen, S.L.1
Morgan, T.R.2
-
100
-
-
33644509858
-
Hepatitis C-identifying patients with progressive liver injury
-
Feld JJ, Liang TJ. Hepatitis C-identifying patients with progressive liver injury. Hepatology 2006;43:S194-S206
-
(2006)
Hepatology
, vol.43
-
-
Feld, J.J.1
Liang, T.J.2
-
101
-
-
12444261843
-
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels
-
Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005;42:266-274
-
(2005)
J Hepatol
, vol.42
, pp. 266-274
-
-
Alberti, A.1
-
102
-
-
15844431546
-
The long-term pathological evolution of chronic hepatitis C
-
Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340
-
(1996)
Hepatology
, vol.23
, pp. 1334-1340
-
-
Yano, M.1
Kumada, H.2
Kage, M.3
Ikeda, K.4
Shimamatsu, K.5
Inoue, O.6
-
103
-
-
0035009810
-
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
-
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001;34:730-739
-
(2001)
J Hepatol
, vol.34
, pp. 730-739
-
-
Poynard, T.1
Ratziu, V.2
Charlotte, F.3
Goodman, Z.4
McHutchison, J.5
Albrecht, J.6
-
104
-
-
34247262422
-
What is mild chronic hepatitis C?
-
Alberti A. What is mild chronic hepatitis C? Hepatol Rev 2005;2:19-23
-
(2005)
Hepatol Rev
, vol.2
, pp. 19-23
-
-
Alberti, A.1
-
105
-
-
0031960043
-
Determinants of outcome of compensated hepatitis C virus-related cirrhosis
-
Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440
-
(1998)
Hepatology
, vol.27
, pp. 1435-1440
-
-
Serfaty, L.1
Aumaitre, H.2
Chazouilleres, O.3
Bonnand, A.M.4
Rosmorduc, O.5
Poupon, R.E.6
-
106
-
-
0029894579
-
The natural history of chronic hepatitis C infection
-
Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-328
-
(1996)
Eur J Gastroenterol Hepatol
, vol.8
, pp. 324-328
-
-
Strader, D.B.1
Seeff, L.B.2
-
107
-
-
0036828840
-
National Institutes of Health Consensus Development Conference: Management of hepatitis C 2002
-
Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-S2
-
(2002)
Hepatology
, vol.36
-
-
Seeff, L.B.1
Hoofnagle, J.H.2
-
108
-
-
43049158112
-
Thrombocytopenia associated with chronic liver disease
-
Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000-1007
-
(2008)
J Hepatol
, vol.48
, pp. 1000-1007
-
-
Afdhal, N.1
McHutchison, J.2
Brown, R.3
Jacobson, I.4
Manns, M.5
Poordad, F.6
-
109
-
-
68949180031
-
Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study
-
Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009;50:393-399
-
(2009)
Hepatology
, vol.50
, pp. 393-399
-
-
Uto, H.1
Stuver, S.O.2
Hayashi, K.3
Kumagai, K.4
Sasaki, F.5
Kanmura, S.6
-
110
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C
-
The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
111
-
-
17144455384
-
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
-
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524
-
(2000)
Ann Intern Med
, vol.132
, pp. 517-524
-
-
Shiratori, Y.1
Imazeki, F.2
Moriyama, M.3
Yano, M.4
Arakawa, Y.5
Yokosuka, O.6
-
112
-
-
1242340418
-
Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study
-
Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455
-
(2004)
Gut
, vol.53
, pp. 451-455
-
-
Ryder, S.D.1
Irving, W.L.2
Jones, D.A.3
Neal, K.R.4
Underwood, J.C.5
-
113
-
-
79953758508
-
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon
-
Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011;53:1100-1108
-
(2011)
Hepatology
, vol.53
, pp. 1100-1108
-
-
Di Bisceglie, A.M.1
Stoddard, A.M.2
Dienstag, J.L.3
Shiffman, M.L.4
Seeff, L.B.5
Bonkovsky, H.L.6
-
114
-
-
63849293362
-
Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India
-
Hissar SS, Kumar M, Tyagi P, Goyal A, Suneetha PV, Agarwal S, et al. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J Gastroenterol Hepatol 2009;24:581-587
-
(2009)
J Gastroenterol Hepatol
, vol.24
, pp. 581-587
-
-
Hissar, S.S.1
Kumar, M.2
Tyagi, P.3
Goyal, A.4
Suneetha, P.V.5
Agarwal, S.6
-
115
-
-
77649134018
-
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection
-
McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology 2010; 138:922-931 e1
-
(2010)
Gastroenterology
, vol.138
-
-
McMahon, B.J.1
Bruden, D.2
Bruce, M.G.3
Livingston, S.4
Christensen, C.5
Homan, C.6
-
116
-
-
79956188487
-
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
-
Barreiro P, Pineda JA, Rallon N, Naggie S, Martin-Carbonero L, Neukam K, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011;203:1629-1636
-
(2011)
J Infect Dis
, vol.203
, pp. 1629-1636
-
-
Barreiro, P.1
Pineda, J.A.2
Rallon, N.3
Naggie, S.4
Martin-Carbonero, L.5
Neukam, K.6
-
117
-
-
82455205743
-
Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus
-
Brandman D, Pingitore A, Lai J, Roberts J, Ferrell L, Bass N, et al. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus. Liver Transpl 2011;17:1380-1386
-
(2011)
Liver Transpl
, vol.17
, pp. 1380-1386
-
-
Brandman, D.1
Pingitore, A.2
Lai, J.3
Roberts, J.4
Ferrell, L.5
Bass, N.6
-
118
-
-
41149156032
-
Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients
-
Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:459-464
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 459-464
-
-
Ohki, T.1
Tateishi, R.2
Sato, T.3
Masuzaki, R.4
Imamura, J.5
Goto, T.6
-
119
-
-
77449150552
-
Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance
-
e1-3
-
Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138:932-941 e1-3
-
(2010)
Gastroenterology
, vol.138
, pp. 932-941
-
-
Milner, K.L.1
Van Der Poorten, D.2
Trenell, M.3
Jenkins, A.B.4
Xu, A.5
Smythe, G.6
-
120
-
-
39549103662
-
Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: Comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients
-
Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008;28:355-362
-
(2008)
Liver Int
, vol.28
, pp. 355-362
-
-
Imazeki, F.1
Yokosuka, O.2
Fukai, K.3
Kanda, T.4
Kojima, H.5
Saisho, H.6
-
121
-
-
0141650631
-
Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C
-
Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H. Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2003;48:1786-1792
-
(2003)
Dig Dis Sci
, vol.48
, pp. 1786-1792
-
-
Imazeki, F.1
Yokosuka, O.2
Fukai, K.3
Hiraide, A.4
Saisho, H.5
-
122
-
-
0033566684
-
Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virusassociated cirrhosis
-
Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virusassociated cirrhosis. Cancer 1999;86:589-595
-
(1999)
Cancer
, vol.86
, pp. 589-595
-
-
Tarao, K.1
Rino, Y.2
Ohkawa, S.3
Shimizu, A.4
Tamai, S.5
Miyakawa, K.6
-
123
-
-
85027954267
-
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma
-
Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011;43:455-458
-
(2011)
Nat Genet
, vol.43
, pp. 455-458
-
-
Kumar, V.1
Kato, N.2
Urabe, Y.3
Takahashi, A.4
Muroyama, R.5
Hosono, N.6
-
124
-
-
0028961434
-
Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients
-
Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-655
-
(1995)
Hepatology
, vol.21
, pp. 650-655
-
-
Takano, S.1
Yokosuka, O.2
Imazeki, F.3
Tagawa, M.4
Omata, M.5
-
125
-
-
17144455384
-
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
-
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524
-
(2000)
Ann Intern Med
, vol.132
, pp. 517-524
-
-
Shiratori, Y.1
Imazeki, F.2
Moriyama, M.3
Yano, M.4
Arakawa, Y.5
Yokosuka, O.6
-
126
-
-
34247138773
-
Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: A 1,386-patient study from Taiwan
-
Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007;25:1029-1037
-
(2007)
Aliment Pharmacol Ther
, Issue.25
, pp. 1029-1037
-
-
Huang, J.F.1
Yu, M.L.2
Lee, C.M.3
Dai, C.Y.4
Hou, N.J.5
Hsieh, M.Y.6
-
127
-
-
0033520109
-
Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy
-
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181
-
(1999)
Ann Intern Med
, vol.131
, pp. 174-181
-
-
Yoshida, H.1
Shiratori, Y.2
Moriyama, M.3
Arakawa, Y.4
Ide, T.5
Sata, M.6
-
128
-
-
0037452519
-
Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus
-
Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306
-
(2003)
Ann Intern Med
, vol.138
, pp. 299-306
-
-
Shiratori, Y.1
Shiina, S.2
Teratani, T.3
Imamura, M.4
Obi, S.5
Sato, S.6
Koike, Y.7
Yoshida, H.8
Omata, M.9
-
129
-
-
33845669536
-
A sustained virological response to interferon or interferon/ ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan
-
Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985-994
-
(2006)
Antivir Ther
, vol.11
, pp. 985-994
-
-
Yu, M.L.1
Lin, S.M.2
Chuang, W.L.3
Dai, C.Y.4
Wang, J.H.5
Lu, S.N.6
-
130
-
-
19944428400
-
Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
-
Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-114
-
(2005)
Ann Intern Med
, vol.142
, pp. 105-114
-
-
Shiratori, Y.1
Ito, Y.2
Yokosuka, O.3
Imazeki, F.4
Nakata, R.5
Tanaka, N.6
-
131
-
-
46149090112
-
Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
-
Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008;49:175-183
-
(2008)
J Hepatol
, vol.49
, pp. 175-183
-
-
Deuffic-Burban, S.1
Deltenre, P.2
Louvet, A.3
Canva, V.4
Dharancy, S.5
Hollebecque, A.6
-
132
-
-
0036320660
-
Interferon therapy prolonged life expectancy among chronic hepatitis C patients
-
Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123: 483-491
-
(2002)
Gastroenterology
, vol.123
, pp. 483-491
-
-
Yoshida, H.1
Arakawa, Y.2
Sata, M.3
Nishiguchi, S.4
Yano, M.5
Fujiyama, S.6
-
133
-
-
0026042112
-
Resolution of acute hepatitis C after therapy with natural beta interferon
-
Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915
-
(1991)
Lancet
, vol.338
, pp. 914-915
-
-
Omata, M.1
Yokosuka, O.2
Takano, S.3
Kato, N.4
Hosoda, K.5
Imazeki, F.6
-
134
-
-
0028106618
-
Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
-
Japan Acute Hepatitis Cooperative Study Group
-
Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994;107:805-811
-
(1994)
Gastroenterology
, vol.107
, pp. 805-811
-
-
Takano, S.1
Satomura, Y.2
Omata, M.3
-
135
-
-
0035892032
-
Treatment of acute hepatitis C with interferon alfa-2b
-
Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457
-
(2001)
N Engl J Med
, vol.345
, pp. 1452-1457
-
-
Jaeckel, E.1
Cornberg, M.2
Wedemeyer, H.3
Santantonio, T.4
Mayer, J.5
Zankel, M.6
-
136
-
-
13844270879
-
Efficacy of a 24-week course of PEGinterferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
-
Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEGinterferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005;42:329-333
-
(2005)
J Hepatol
, vol.42
, pp. 329-333
-
-
Santantonio, T.1
Fasano, M.2
Sinisi, E.3
Guastadisegni, A.4
Casalino, C.5
Mazzola, M.6
-
137
-
-
33644857481
-
Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response
-
Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-638
-
(2006)
Gastroenterology
, vol.130
, pp. 632-638
-
-
Kamal, S.M.1
Fouly, A.E.2
Kamel, R.R.3
Hockenjos, B.4
Al Tawil, A.5
Khalifa, K.E.6
-
138
-
-
76649112731
-
Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany
-
Dintsios CM, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, et al. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 2010;22:278-288
-
(2010)
Eur J Gastroenterol Hepatol
, vol.22
, pp. 278-288
-
-
Dintsios, C.M.1
Haverkamp, A.2
Wiegand, J.3
Gerlach, T.4
Wedemeyer, H.5
Pape, G.6
-
139
-
-
34250320980
-
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
-
Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832-836
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 832-836
-
-
Yu, J.W.1
Wang, G.Q.2
Sun, L.J.3
Li, X.G.4
Li, S.C.5
-
140
-
-
70349242026
-
Peginterferon alpha-2a (40 kDa) and ribavirin: Comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients
-
Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009;16:724-731
-
(2009)
J Viral Hepat
, vol.16
, pp. 724-731
-
-
Reddy, K.R.1
Messinger, D.2
Popescu, M.3
Hadziyannis, S.J.4
-
141
-
-
77949773445
-
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
-
Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405-408
-
(2010)
Nature
, vol.464
, pp. 405-408
-
-
Fellay, J.1
Thompson, A.J.2
Ge, D.3
Gumbs, C.E.4
Urban, T.J.5
Shianna, K.V.6
-
142
-
-
61849108171
-
Insulin resistance predicts response to peginterferon-alpha/ ribavirin combination therapy in chronic hepatitis C patients
-
Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50:712-718
-
(2009)
J Hepatol
, vol.50
, pp. 712-718
-
-
Dai, C.Y.1
Huang, J.F.2
Hsieh, M.Y.3
Hou, N.J.4
Lin, Z.Y.5
Chen, S.C.6
-
143
-
-
77951576906
-
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
-
Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51:1523-1530
-
(2010)
Hepatology
, vol.51
, pp. 1523-1530
-
-
Askarieh, G.1
Alsio, A.2
Pugnale, P.3
Negro, F.4
Ferrari, C.5
Neumann, A.U.6
-
144
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
-
145
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109
-
(2009)
Nat Genet
, vol.41
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
Kurosaki, M.4
Matsuura, K.5
Sakamoto, N.6
-
146
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
Berg, T.4
Weltman, M.5
Abate, M.L.6
-
147
-
-
84925580987
-
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
-
827 e1
-
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-827, 827 e1
-
(2010)
Gastroenterology
, vol.139
, pp. 821-827
-
-
Mangia, A.1
Thompson, A.J.2
Santoro, R.3
Piazzolla, V.4
Tillmann, H.L.5
Patel, K.6
-
148
-
-
78649320722
-
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
-
Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011;53:7-13
-
(2011)
Hepatology
, vol.53
, pp. 7-13
-
-
Yu, M.L.1
Huang, C.F.2
Huang, J.F.3
Chang, N.C.4
Yang, J.F.5
Lin, Z.Y.6
-
149
-
-
0037008087
-
Updated definitions of healthy ranges for serum alanine aminotransferase levels
-
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10
-
(2002)
Ann Intern Med
, vol.137
, pp. 1-10
-
-
Prati, D.1
Taioli, E.2
Zanella, A.3
Della Torre, E.4
Butelli, S.5
Del Vecchio, E.6
-
150
-
-
0037126675
-
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection
-
Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961-964
-
(2002)
Ann Intern Med
, vol.137
, pp. 961-964
-
-
Alberti, A.1
Noventa, F.2
Benvegnu, L.3
Boccato, S.4
Gatta, A.5
-
151
-
-
0037383495
-
A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase
-
Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-517
-
(2003)
J Hepatol
, vol.38
, pp. 511-517
-
-
Hui, C.K.1
Belaye, T.2
Montegrande, K.3
Wright, T.L.4
-
152
-
-
9644262441
-
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
-
Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732
-
(2004)
Gastroenterology
, vol.127
, pp. 1724-1732
-
-
Zeuzem, S.1
Diago, M.2
Gane, E.3
Reddy, K.R.4
Pockros, P.5
Prati, D.6
-
153
-
-
33748883014
-
Review article: Management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity
-
Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, et al. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 2006;24:1133-1149
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 1133-1149
-
-
Zeuzem, S.1
Alberti, A.2
Rosenberg, W.3
Marcellin, P.4
Diago, M.5
Negro, F.6
-
154
-
-
33845310369
-
Optimizing treatment regimens in hepatitis C
-
Darling JM, Fried MW. Optimizing treatment regimens in hepatitis C. Clin Liver Dis 2006;10:835-850
-
(2006)
Clin Liver Dis
, vol.10
, pp. 835-850
-
-
Darling, J.M.1
Fried, M.W.2
-
155
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr., F.L.6
-
156
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
-
157
-
-
36348981708
-
Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic hepatitis C patients: A randomized trial
-
Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic
-
(2007)
Hepatology
, vol.46
, pp. 971-981
-
-
Jacobson, I.M.1
Brown Jr., R.S.2
Freilich, B.3
Afdhal, N.4
Kwo, P.Y.5
Santoro, J.6
-
158
-
-
0032585237
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
-
International Hepatitis Interventional Therapy Group (IHIT)
-
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432
-
(1998)
Lancet
, vol.352
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
Niederau, C.4
Minuk, G.S.5
Ideo, G.6
-
159
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
Manns, M.P.4
Harvey, J.5
Albrecht, J.6
-
160
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
-
161
-
-
58949099266
-
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
-
Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49:22-31
-
(2009)
Hepatology
, vol.49
, pp. 22-31
-
-
Laguno, M.1
Cifuentes, C.2
Murillas, J.3
Veloso, S.4
Larrousse, M.5
Payeras, A.6
-
162
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
Muir, A.J.4
Galler, G.W.5
McCone, J.6
-
163
-
-
72249083270
-
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
-
Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-115
-
(2010)
Gastroenterology
, vol.138
, pp. 108-115
-
-
Rumi, M.G.1
Aghemo, A.2
Prati, G.M.3
D'ambrosio, R.4
Donato, M.F.5
Soffredini, R.6
-
164
-
-
72249094116
-
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
-
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138:116-122
-
(2010)
Gastroenterology
, vol.138
, pp. 116-122
-
-
Ascione, A.1
De Luca, M.2
Tartaglione, M.T.3
Lampasi, F.4
Di Costanzo, G.G.5
Lanza, A.G.6
-
165
-
-
77953575515
-
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE study
-
Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010;17:459-468
-
(2010)
J Viral Hepat
, vol.17
, pp. 459-468
-
-
Witthoeft, T.1
Hueppe, D.2
John, C.3
Goelz, J.4
Heyne, R.5
Moeller, B.6
-
166
-
-
77950622393
-
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials
-
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-1184
-
(2010)
Hepatology
, vol.51
, pp. 1176-1184
-
-
Awad, T.1
Thorlund, K.2
Hauser, G.3
Stimac, D.4
Mabrouk, M.5
Gluud, C.6
-
167
-
-
0033919083
-
Adverse effects and other safety aspects of the hepatitis C antivirals
-
Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000;15 Suppl: E156-E163
-
(2000)
J Gastroenterol Hepatol
, vol.15 SUPPL.
-
-
Chutaputti, A.1
-
168
-
-
46249129460
-
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
-
Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-1845
-
(2008)
Hepatology
, vol.47
, pp. 1837-1845
-
-
Lagging, M.1
Langeland, N.2
Pedersen, C.3
Farkkila, M.4
Buhl, M.R.5
Morch, K.6
-
169
-
-
38649090068
-
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
-
Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42
-
(2008)
Hepatology
, vol.47
, pp. 35-42
-
-
Dalgard, O.1
Bjoro, K.2
Ring-Larsen, H.3
Bjornsson, E.4
Holberg-Petersen, M.5
Skovlund, E.6
-
170
-
-
10644264391
-
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
-
Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-1265
-
(2004)
Hepatology
, vol.40
, pp. 1260-1265
-
-
Dalgard, O.1
Bjoro, K.2
Hellum, K.B.3
Myrvang, B.4
Ritland, S.5
Skaug, K.6
-
171
-
-
34447318385
-
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
-
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134
-
(2007)
N Engl J Med
, vol.357
, pp. 124-134
-
-
Shiffman, M.L.1
Suter, F.2
Bacon, B.R.3
Nelson, D.4
Harley, H.5
Sola, R.6
-
172
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103
-
(2006)
J Hepatol
, vol.44
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
Sperl, J.4
Horsmans, Y.5
Cianciara, J.6
-
173
-
-
2442683905
-
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
-
Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999
-
(2004)
J Hepatol
, vol.40
, pp. 993-999
-
-
Zeuzem, S.1
Hultcrantz, R.2
Bourliere, M.3
Goeser, T.4
Marcellin, P.5
Sanchez-Tapias, J.6
-
174
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617
-
(2005)
N Engl J Med
, vol.352
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
Ricci, G.L.4
Carretta, V.5
Persico, M.6
-
175
-
-
33645992473
-
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin
-
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097
-
(2006)
Gastroenterology
, vol.130
, pp. 1086-1097
-
-
Berg, T.1
Von Wagner, M.2
Nasser, S.3
Sarrazin, C.4
Heintges, T.5
Gerlach, T.6
-
176
-
-
37749051824
-
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
-
Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007;46:1688-1694
-
(2007)
Hepatology
, vol.46
, pp. 1688-1694
-
-
Pearlman, B.L.1
Ehleben, C.2
Saifee, S.3
-
177
-
-
75449111848
-
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response
-
512 e1
-
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138:503-512, 512 e1
-
(2010)
Gastroenterology
, vol.138
, pp. 503-512
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Maieron, A.4
Hofer, H.5
Stauber, R.6
-
178
-
-
77957952655
-
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
-
Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010;52:1201-1207
-
(2010)
Hepatology
, vol.52
, pp. 1201-1207
-
-
Buti, M.1
Lurie, Y.2
Zakharova, N.G.3
Blokhina, N.P.4
Horban, A.5
Teuber, G.6
-
179
-
-
0033920185
-
What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?
-
Sarin SK. What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? J Gastroenterol Hepatol 2000;15 Suppl:E164-E171
-
(2000)
J Gastroenterol Hepatol
, vol.15 SUPPL.
-
-
Sarin, S.K.1
-
180
-
-
36749040213
-
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C
-
Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747-1753
-
(2007)
Gut
, vol.56
, pp. 1747-1753
-
-
Omata, M.1
Yoshida, H.2
Toyota, J.3
Tomita, E.4
Nishiguchi, S.5
Hayashi, N.6
-
181
-
-
17344368726
-
Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
-
Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998;27:1128-1135
-
(1998)
Hepatology
, vol.27
, pp. 1128-1135
-
-
Sherman, K.E.1
Sjogren, M.2
Creager, R.L.3
Damiano, M.A.4
Freeman, S.5
Lewey, S.6
-
182
-
-
79960744370
-
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
-
Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-540
-
(2011)
Hepatology
, vol.54
, pp. 532-540
-
-
Yoshida, H.1
Shiratori, Y.2
Kudo, M.3
Shiina, S.4
Mizuta, T.5
Kojiro, M.6
-
183
-
-
66149129922
-
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients
-
Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009;49:1460-1468
-
(2009)
Hepatology
, vol.49
, pp. 1460-1468
-
-
Flisiak, R.1
Feinman, S.V.2
Jablkowski, M.3
Horban, A.4
Kryczka, W.5
Pawlowska, M.6
-
184
-
-
40949117600
-
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
-
Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-826
-
(2008)
Hepatology
, vol.47
, pp. 817-826
-
-
Flisiak, R.1
Horban, A.2
Gallay, P.3
Bobardt, M.4
Selvarajah, S.5
Wiercinska-Drapalo, A.6
-
185
-
-
55249084176
-
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ ribavirin therapy
-
Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ ribavirin therapy. Gastroenterology 2008;135:1561-1567
-
(2008)
Gastroenterology
, vol.135
, pp. 1561-1567
-
-
Ferenci, P.1
Scherzer, T.M.2
Kerschner, H.3
Rutter, K.4
Beinhardt, S.5
Hofer, H.6
-
186
-
-
57349116772
-
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
-
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441
-
(2008)
N Engl J Med
, vol.359
, pp. 2429-2441
-
-
Di Bisceglie, A.M.1
Shiffman, M.L.2
Everson, G.T.3
Lindsay, K.L.4
Everhart, J.E.5
Wright, E.C.6
-
187
-
-
79952316752
-
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
-
quiz e12
-
Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140:840-849 (quiz e12)
-
(2011)
Gastroenterology
, vol.140
, pp. 840-849
-
-
Lok, A.S.1
Everhart, J.E.2
Wright, E.C.3
Di Bisceglie, A.M.4
Kim, H.Y.5
Sterling, R.K.6
-
188
-
-
79958177731
-
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C
-
Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990-1999
-
(2011)
Gastroenterology
, vol.140
, pp. 1990-1999
-
-
Bruix, J.1
Poynard, T.2
Colombo, M.3
Schiff, E.4
Burak, K.5
Heathcote, E.J.6
-
189
-
-
0033937190
-
Hepatitis C: Retreatment and treatment of patients with renal failure
-
E152-E155
-
Chow WC. Hepatitis C: retreatment and treatment of patients with renal failure. J Gastroenterol Hepatol 2000;15 Suppl:E152-E155
-
(2000)
J Gastroenterol Hepatol
, vol.15 SUPPL.
-
-
Chow, W.C.1
-
190
-
-
11144358311
-
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
-
discussion 947
-
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023. (discussion 947)
-
(2004)
Gastroenterology
, vol.126
, pp. 1015-1023
-
-
Shiffman, M.L.1
Di Bisceglie, A.M.2
Lindsay, K.L.3
Morishima, C.4
Wright, E.C.5
Everson, G.T.6
-
191
-
-
33646001297
-
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients
-
Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006;130:1098-1106
-
(2006)
Gastroenterology
, vol.130
, pp. 1098-1106
-
-
Taliani, G.1
Gemignani, G.2
Ferrari, C.3
Aceti, A.4
Bartolozzi, D.5
Blanc, P.L.6
-
192
-
-
67349172961
-
Peginterferon alfa-2b and ribavirin: Effective in patientswith hepatitis C who failed interferon alfa/ribavirin therapy
-
e2
-
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patientswith hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2099; 136:1618-1628 e2
-
Gastroenterology
, vol.2099
, Issue.136
, pp. 1618-1628
-
-
Poynard, T.1
Colombo, M.2
Bruix, J.3
Schiff, E.4
Terg, R.5
Flamm, S.6
-
193
-
-
66949176133
-
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
-
Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009;49: 1838-1846
-
(2009)
Hepatology
, vol.49
, pp. 1838-1846
-
-
Bacon, B.R.1
Shiffman, M.L.2
Mendes, F.3
Ghalib, R.4
Hassanein, T.5
Morelli, G.6
-
194
-
-
65349129985
-
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferonalpha2b: A randomized trial
-
Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferonalpha2b: a randomized trial. Ann Intern Med 2009;150:528-540
-
(2009)
Ann Intern Med
, vol.150
, pp. 528-540
-
-
Jensen, D.M.1
Marcellin, P.2
Freilich, B.3
Andreone, P.4
Di Bisceglie, A.5
Brandao-Mello, C.E.6
-
195
-
-
69949167624
-
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
-
Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, et al. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol 2009;51:675-681
-
(2009)
J Hepatol
, vol.51
, pp. 675-681
-
-
Camma, C.1
Cabibbo, G.2
Bronte, F.3
Enea, M.4
Licata, A.5
Attanasio, M.6
-
196
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
-
197
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
-
198
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
-
199
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
-
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458
-
(2008)
Gastroenterology
, vol.135
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
Gschwantler, M.4
Maieron, A.5
Brunner, H.6
-
200
-
-
21144449073
-
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response
-
Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-866
-
(2005)
Gut
, vol.54
, pp. 858-866
-
-
Kamal, S.M.1
El Tawil, A.A.2
Nakano, T.3
He, Q.4
Rasenack, J.5
Hakam, S.A.6
-
201
-
-
37749046123
-
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
-
Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007;46:1732-1740
-
(2007)
Hepatology
, vol.46
, pp. 1732-1740
-
-
Kamal, S.M.1
El Kamary, S.S.2
Shardell, M.D.3
Hashem, M.4
Ahmed, I.N.5
Muhammadi, M.6
-
202
-
-
55949132364
-
Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa
-
Prabdial-Sing N, Puren AJ, Mahlangu J, Barrow P, Bowyer SM. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol 2008;153:2049-2058
-
(2008)
Arch Virol
, vol.153
, pp. 2049-2058
-
-
Prabdial-Sing, N.1
Puren, A.J.2
Mahlangu, J.3
Barrow, P.4
Bowyer, S.M.5
-
203
-
-
22044440709
-
Chronic hepatitis C: Genotypes 4 to 9
-
vi
-
Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005; 9:411-426, vi
-
(2005)
Clin Liver Dis
, vol.9
, pp. 411-426
-
-
Nguyen, M.H.1
Keeffe, E.B.2
-
204
-
-
26444432835
-
Prevalence and treatment of hepatitis C virus genotypes 4,5, and 6
-
S97-S101
-
Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005;3:S97-S101
-
(2005)
Clin Gastroenterol Hepatol
, vol.3
-
-
Nguyen, M.H.1
Keeffe, E.B.2
-
205
-
-
43549108337
-
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin
-
Nguyen MH,Trinh HN,Garcia R, Nguyen G,Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008;103:1131-1135
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1131-1135
-
-
Nguyen, M.H.1
Trinh, H.N.2
Garcia, R.3
Nguyen, G.4
Lam, K.D.5
Keeffe, E.B.6
-
206
-
-
51749084677
-
Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin
-
Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198:808-812
-
(2008)
J Infect Dis
, vol.198
, pp. 808-812
-
-
Fung, J.1
Lai, C.L.2
Hung, I.3
Young, J.4
Cheng, C.5
Wong, D.6
-
207
-
-
78049512501
-
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
-
Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, Nguyen T, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010;52:1573-1580
-
(2010)
Hepatology
, vol.52
, pp. 1573-1580
-
-
Lam, K.D.1
Trinh, H.N.2
Do, S.T.3
Nguyen, T.T.4
Garcia, R.T.5
Nguyen, T.6
-
208
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
-
209
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
-
210
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
-
211
-
-
78650820415
-
Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatmentnaïve patients: Final results of phase 3 ADVANCE study
-
abstract 211
-
Jacobson JM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy R, Bzowei NH, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatmentnaïve patients: final results of phase 3 ADVANCE study. Hepatology 2010;52:112. (abstract 211)
-
(2010)
Hepatology
, vol.52
, pp. 112
-
-
Jacobson, J.M.1
McHutchison, J.G.2
Dusheiko, G.M.3
Di Bisceglie, A.M.4
Reddy, R.5
Bzowei, N.H.6
-
212
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-1303
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
Terrault, N.A.4
Jacobson, I.M.5
Afdhal, N.H.6
-
213
-
-
77956268467
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial
-
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-716
-
(2010)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
Schiff, E.R.4
Vierling, J.M.5
Pound, D.6
-
214
-
-
80052353429
-
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives
-
Liu CH, Kao JH. Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 2011;26:1348-1353
-
(2011)
J Gastroenterol Hepatol
, vol.26
, pp. 1348-1353
-
-
Liu, C.H.1
Kao, J.H.2
-
215
-
-
34247594930
-
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
-
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777
-
(2007)
Gastroenterology
, vol.132
, pp. 1767-1777
-
-
Sarrazin, C.1
Kieffer, T.L.2
Bartels, D.3
Hanzelka, B.4
Muh, U.5
Welker, M.6
-
216
-
-
34548758435
-
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
-
Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639
-
(2007)
Hepatology
, vol.46
, pp. 631-639
-
-
Kieffer, T.L.1
Sarrazin, C.2
Miller, J.S.3
Welker, M.W.4
Forestier, N.5
Reesink, H.W.6
-
217
-
-
73149113353
-
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
-
Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-1718
-
(2009)
Hepatology
, vol.50
, pp. 1709-1718
-
-
Susser, S.1
Welsch, C.2
Wang, Y.3
Zettler, M.4
Domingues, F.S.5
Karey, U.6
-
218
-
-
61849172935
-
Safety pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment
-
Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009;14:23-32
-
(2009)
Antivir Ther
, vol.14
, pp. 23-32
-
-
Erhardt, A.1
Deterding, K.2
Benhamou, Y.3
Reiser, M.4
Forns, X.5
Pol, S.6
-
219
-
-
84862857031
-
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
-
epub ahead of print
-
Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2011; (epub ahead of print)
-
(2011)
J Hepatol
-
-
Kumada, H.1
Toyota, J.2
Okanoue, T.3
Chayama, K.4
Tsubouchi, H.5
Hayashi, N.6
-
220
-
-
84855972024
-
Dermatological side effects of hepatitis c and its treatment: Patient management in the era of direct-acting antivirals
-
epub ahead of print
-
Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis c and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2011; (epub ahead of print)
-
(2011)
J Hepatol
-
-
Cacoub, P.1
Bourliere, M.2
Lubbe, J.3
Dupin, N.4
Buggisch, P.5
Dusheiko, G.6
-
221
-
-
23044500773
-
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
-
Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262
-
(2005)
Hepatology
, vol.42
, pp. 255-262
-
-
Everson, G.T.1
Trotter, J.2
Forman, L.3
Kugelmas, M.4
Halprin, A.5
Fey, B.6
-
222
-
-
34548487937
-
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis
-
Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824
-
(2007)
Gastroenterology
, vol.133
, pp. 818-824
-
-
Fernandez, J.1
Navasa, M.2
Planas, R.3
Montoliu, S.4
Monfort, D.5
Soriano, G.6
-
223
-
-
33845658184
-
Antiviral therapy in HCV decompensated cirrhosis: To treat or not to treat?
-
Navasa M, Forns X. Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat? J Hepatol 2007;46:185-188
-
(2007)
J Hepatol
, vol.46
, pp. 185-188
-
-
Navasa, M.1
Forns, X.2
-
224
-
-
60749126501
-
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease
-
Kidney Disease: Improving Global Outcomes (2008) KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl S1-S99
-
(2008)
Kidney Int Suppl
-
-
Disease, K.1
Global Outcomes, I.2
-
225
-
-
34548682796
-
Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis
-
Butt AA, Skanderson M, McGinnis KA, Ahuja T, Bryce CL, Barnato AE, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat 2007;14:688-696
-
(2007)
J Viral Hepat
, vol.14
, pp. 688-696
-
-
Butt, A.A.1
Skanderson, M.2
McGinnis, K.A.3
Ahuja, T.4
Bryce, C.L.5
Barnato, A.E.6
-
226
-
-
72949097936
-
Hepatitis C progressing to hepatocellular carcinoma: The HCV dialysis patient in dilemma
-
Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, et al. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59-64
-
(2010)
J Viral Hepat
, vol.17
, pp. 59-64
-
-
Henderson, W.A.1
Shankar, R.2
Gill, J.M.3
Kim, K.H.4
Ghany, M.G.5
Skanderson, M.6
-
227
-
-
41149086703
-
Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study
-
Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525-530
-
(2008)
Gut
, vol.57
, pp. 525-530
-
-
Liu, C.H.1
Liang, C.C.2
Lin, J.W.3
Chen, S.I.4
Tsai, H.B.5
Chang, C.S.6
-
228
-
-
37649006377
-
Interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
-
Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008;15:79-88
-
(2008)
J Viral Hepat
, vol.15
, pp. 79-88
-
-
Fabrizi, F.1
Dixit, V.2
Messa, P.3
Martin, P.4
-
229
-
-
56149114504
-
Treatment of chronic hepatitis C in hemodialysis patients
-
Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48:1690-1699
-
(2008)
Hepatology
, vol.48
, pp. 1690-1699
-
-
Berenguer, M.1
-
230
-
-
84984549622
-
Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
-
Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009;58:314-316
-
(2009)
Gut
, vol.58
, pp. 314-316
-
-
Liu, C.H.1
Liang, C.C.2
Liu, C.J.3
Tsai, H.B.4
Hung, P.H.5
Hsu, S.J.6
-
231
-
-
34047153283
-
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant
-
Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768-774
-
(2007)
J Hepatol
, vol.46
, pp. 768-774
-
-
Rendina, M.1
Schena, A.2
Castellaneta, N.M.3
Losito, F.4
Amoruso, A.C.5
Stallone, G.6
-
232
-
-
78851469938
-
Treatment of hepatitis C virus infection in patients with end-stage renal disease
-
Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011;26:228-239
-
(2011)
J Gastroenterol Hepatol
, vol.26
, pp. 228-239
-
-
Liu, C.H.1
Kao, J.H.2
-
234
-
-
33645998423
-
Mortality and causes of death in patients with hemophilia, 1992-2001: A prospective cohort study
-
Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-516
-
(2006)
J Thromb Haemost
, vol.4
, pp. 510-516
-
-
Plug, I.1
Van Der Bom, J.G.2
Peters, M.3
Mauser-Bunschoten, E.P.4
De Goede-Bolder, A.5
Heijnen, L.6
-
235
-
-
31544434879
-
Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia
-
Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006;107:892-897
-
(2006)
Blood
, vol.107
, pp. 892-897
-
-
Zhang, M.1
Rosenberg, P.S.2
Brown, D.L.3
Preiss, L.4
Konkle, B.A.5
Eyster, M.E.6
-
236
-
-
34247228431
-
Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: Can you avoid liver biopsy?
-
Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006;12:372-379
-
(2006)
Haemophilia
, vol.12
, pp. 372-379
-
-
Maor, Y.1
Bashari, D.2
Kenet, G.3
Lubetsky, A.4
Luboshitz, J.5
Schapiro, J.M.6
-
237
-
-
33645566188
-
Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: A possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin
-
Yamamoto K, Honda T, Matsushita T, Kojima T, Takamatsu J. Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin. J Thromb Haemost 2006;4:469-470
-
(2006)
J Thromb Haemost
, vol.4
, pp. 469-470
-
-
Yamamoto, K.1
Honda, T.2
Matsushita, T.3
Kojima, T.4
Takamatsu, J.5
-
238
-
-
77950233870
-
Treatment of chronic hepatitis C in polytransfused thalassaemic patients: A meta-analysis
-
Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat 2010;17:236-244
-
(2010)
J Viral Hepat
, vol.17
, pp. 236-244
-
-
Alavian, S.M.1
Tabatabaei, S.V.2
-
239
-
-
77956635110
-
Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C
-
Sood A, Sobti P, Midha V, Singla D, Kaur A, Kaushal S, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010;29:62-65
-
(2010)
Indian J Gastroenterol
, vol.29
, pp. 62-65
-
-
Sood, A.1
Sobti, P.2
Midha, V.3
Singla, D.4
Kaur, A.5
Kaushal, S.6
-
240
-
-
0026767145
-
Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: Comparison with adult blood donors
-
Tanaka E, Kiyosawa K, Sodeyama T, Hayata T, Ohike Y, Nakano Y, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg 1992;46:460-464
-
(1992)
Am J Trop Med Hyg
, vol.46
, pp. 460-464
-
-
Tanaka, E.1
Kiyosawa, K.2
Sodeyama, T.3
Hayata, T.4
Ohike, Y.5
Nakano, Y.6
-
241
-
-
33747161320
-
Hepatitis B and C: Prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan
-
Jafri W, Jafri N, Yakoob J, Islam M, Tirmizi SF, Jafar T, et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 2006;6:101
-
(2006)
BMC Infect Dis
, vol.6
, pp. 101
-
-
Jafri, W.1
Jafri, N.2
Yakoob, J.3
Islam, M.4
Tirmizi, S.F.5
Jafar, T.6
-
242
-
-
28944437346
-
Seroepidemiology of hepatitis A, B, C, and e viruses infection among preschool children in Taiwan
-
Lin JB, Lin DB, Chen SC, Chen PS, Chen WK. Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan. J Med Virol 2006;78:18-23
-
(2006)
J Med Virol
, vol.78
, pp. 18-23
-
-
Lin, J.B.1
Lin, D.B.2
Chen, S.C.3
Chen, P.S.4
Chen, W.K.5
-
243
-
-
27944481200
-
Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy
-
Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-189
-
(2005)
J Infect Dis
, vol.192
, pp. 1880-2189
-
-
Mast, E.E.1
Hwang, L.Y.2
Seto, D.S.3
Nolte, F.S.4
Nainan, O.V.5
Wurtzel, H.6
-
244
-
-
27944447629
-
A significant sex-but not elective cesarean section-effect on mother-tochild transmission of hepatitis C virus infection
-
European Paediatric Hepatitis C Virus Network
-
European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-tochild transmission of hepatitis C virus infection. J Infect Dis 2005;192:1872-1879
-
(2005)
J Infect Dis
, vol.192
, pp. 1872-1879
-
-
-
245
-
-
33646790899
-
Longitudinal long-term follow-up study of children with vertically acquired hepatitis C virus infection
-
Zuccotti GV, Salvini F, Farina F, Agostoni C, Riva E, Giovannini M. Longitudinal long-term follow-up study of children with vertically acquired hepatitis C virus infection. J Int Med Res 2006;34:215-222
-
(2006)
J Int Med Res
, vol.34
, pp. 215-222
-
-
Zuccotti, G.V.1
Salvini, F.2
Farina, F.3
Agostoni, C.4
Riva, E.5
Giovannini, M.6
-
246
-
-
77952419827
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents
-
Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827-831
-
(2010)
J Hepatol
, vol.52
, pp. 827-831
-
-
Sokal, E.M.1
Bourgois, A.2
Stephenne, X.3
Silveira, T.4
Porta, G.5
Gardovska, D.6
-
247
-
-
34047104430
-
Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period
-
Bortolotti F, Iorio R, Resti M, Camma C, Marcellini M, Giacchino R, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007;46:783-790
-
(2007)
J Hepatol
, vol.46
, pp. 783-790
-
-
Bortolotti, F.1
Iorio, R.2
Resti, M.3
Camma, C.4
Marcellini, M.5
Giacchino, R.6
-
248
-
-
35248854271
-
Spontaneous clearance of childhood hepatitis C virus infection
-
Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat 2007;14:797-805
-
(2007)
J Viral Hepat
, vol.14
, pp. 797-805
-
-
Yeung, L.T.1
To, T.2
King, S.M.3
Roberts, E.A.4
-
249
-
-
40949103932
-
Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial
-
Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836-843
-
(2008)
Hepatology
, vol.47
, pp. 836-843
-
-
Goodman, Z.D.1
Makhlouf, H.R.2
Liu, L.3
Balistreri, W.4
Gonzalez-Peralta, R.P.5
Haber, B.6
-
250
-
-
77949816251
-
SAFETY study: Alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease
-
1364 e1-2
-
Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138:1357-1364, 1364 e1-2
-
(2010)
Gastroenterology
, vol.138
, pp. 1357-1364
-
-
Schwimmer, J.B.1
Dunn, W.2
Norman, G.J.3
Pardee, P.E.4
Middleton, M.S.5
Kerkar, N.6
-
251
-
-
34447337270
-
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
-
Nunez M, Marino A, Miralles C, Berdun MA, Sola J, Hernandez-Burruezo JJ, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:439-444
-
(2007)
J Acquir Immune Defic Syndr
, vol.45
, pp. 439-444
-
-
Nunez, M.1
Marino, A.2
Miralles, C.3
Berdun, M.A.4
Sola, J.5
Hernandez-Burruezo, J.J.6
-
252
-
-
37349071425
-
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
-
Martin-Carbonero L, Nunez M, Marino A, Alcocer F, Bonet L, Garcia-Samaniego J, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008;22:15-21
-
(2008)
AIDS
, vol.22
, pp. 15-21
-
-
Martin-Carbonero, L.1
Nunez, M.2
Marino, A.3
Alcocer, F.4
Bonet, L.5
Garcia-Samaniego, J.6
-
253
-
-
68949183159
-
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
-
Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413
-
(2009)
Hepatology
, vol.50
, pp. 407-413
-
-
Berenguer, J.1
Alvarez-Pellicer, J.2
Martin, P.M.3
Lopez-Aldeguer, J.4
Von-Wichmann, M.A.5
Quereda, C.6
-
254
-
-
77957825574
-
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
-
Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010;51:788-795
-
(2010)
Clin Infect Dis
, vol.51
, pp. 788-795
-
-
Pineda, J.A.1
Caruz, A.2
Rivero, A.3
Neukam, K.4
Salas, I.5
Camacho, A.6
-
255
-
-
79952655262
-
Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort
-
Clausen LN, Weis N, Astvad K, Schonning K, Fenger M, Krarup H, et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 2011;18:e66-e74
-
(2011)
J Viral Hepat
, vol.18
-
-
Clausen, L.N.1
Weis, N.2
Astvad, K.3
Schonning, K.4
Fenger, M.5
Krarup, H.6
-
256
-
-
77951880384
-
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients
-
Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-F29
-
(2010)
AIDS
, vol.24
-
-
Rallon, N.I.1
Naggie, S.2
Benito, J.M.3
Medrano, J.4
Restrepo, C.5
Goldstein, D.6
-
257
-
-
84984585800
-
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
-
e3
-
Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136:496-504 e3
-
(2009)
Gastroenterology
, vol.136
, pp. 496-504
-
-
Liu, C.J.1
Chuang, W.L.2
Lee, C.M.3
Yu, M.L.4
Lu, S.N.5
Wu, S.S.6
-
258
-
-
72449191348
-
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin
-
Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009;44:1487-1490
-
(2009)
Scand J Gastroenterol
, vol.44
, pp. 1487-1490
-
-
Potthoff, A.1
Berg, T.2
Wedemeyer, H.3
-
259
-
-
79958713034
-
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
-
Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011;6:e20752
-
(2011)
PLoS One
, vol.6
-
-
Yeh, M.L.1
Hung, C.H.2
Huang, J.F.3
Liu, C.J.4
Lee, C.M.5
Dai, C.Y.6
-
260
-
-
77953725569
-
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
-
Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010;202:86-92
-
(2010)
J Infect Dis
, vol.202
, pp. 86-92
-
-
Yu, M.L.1
Lee, C.M.2
Chuang, W.L.3
Lu, S.N.4
Dai, C.Y.5
Huang, J.F.6
-
261
-
-
9144257569
-
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
-
Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81
-
(1996)
N Engl J Med
, vol.334
, pp. 77-81
-
-
Enomoto, N.1
Sakuma, I.2
Asahina, Y.3
Kurosaki, M.4
Murakami, T.5
Yamamoto, C.6
-
262
-
-
47149083069
-
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ ribavirin combination therapy
-
El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ ribavirin combination therapy. Hepatology 2008;48:38-47
-
(2008)
Hepatology
, vol.48
, pp. 38-47
-
-
El-Shamy, A.1
Nagano-Fujii, M.2
Sasase, N.3
Imoto, S.4
Kim, S.R.5
Hotta, H.6
|